Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Legend Biotech Corp ADR
(NQ:
LEGN
)
47.12
-1.71 (-3.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Legend Biotech Corp ADR
< Previous
1
2
3
Next >
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
April 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
April 05, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
March 19, 2024
From
Legend Biotech Corporation
Via
Business Wire
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
March 15, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
March 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
February 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
February 13, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3
January 03, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Legend Biotech Corporation
Via
Business Wire
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
December 11, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
November 20, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3
November 13, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Investor Conference Call on Third-Quarter Results
November 07, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
November 02, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
August 15, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Investor Conference Call on Second-Quarter Results
August 03, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
June 06, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
June 02, 2023
From
Legend Biotech
Via
Business Wire
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
June 05, 2023
From
Legend Biotech
Via
Business Wire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
May 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
May 25, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
May 18, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
May 16, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conference
May 11, 2023
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
May 08, 2023
From
Legend Biotech Corporation
Via
Business Wire
Why Legend Biotech Stock Is Having Its Best Month Yet
April 25, 2023
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.
Via
MarketBeat
Legend Biotech Corp. (NASDAQ: LEGN) Leading the Way in Wednesday Trading Based on Percentage Gain
April 19, 2023
Via
Investor Brand Network
Legend Biotech Announces Appointment of Chief Medical Officer
April 11, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech Establishes Strategic Advisory Board
April 03, 2023
From
Legend Biotech
Via
Business Wire
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
March 30, 2023
From
Legend Biotech
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.